Softhale successfully completed its first surveillance audit on ISO 13485, so the license will be retained –March 2022
The Board of Directors of Sino Biopharmaceutical Limited announces that on 22 March 2021, invoX Pharma Ltd, a wholly-owned subsidiary of the Company, entered into an agreement in relation to a 100% acquisition of Softhale NV.
Successful series B fundraising –February 2019
Softhale’s proprietary device technology is protected by 15+ patents. Our portfolio also expanded with a branded high-end product. Our current activities are financed by the successful series B fundraising closed in early 2019.
Internal team growth –December 2018
In 2018 and 2019, the internal team grew with the recruitment of leading industry experts in the respiratory field with a long track record of bringing inhalable branded and generic products to market.
Softhale’s first laboratory was opened –August 2017
Softhale moves into the office in Diepenbeek, Belgium –April 2017
Series A round successfully completed –December 2016
Completed a successful Series A round, a more than €1 million grant, and a first customer-funded proof-of-concept study.
Softhale NV was established in Diepenbeek, Belgium –February 2016
Early-stage proof-of-concept work –February 2015
Business plan creation –January 2014
The team conducted concept validation work and initial freedom-to-operate analysis, followed by the creation of a business plan. This plan helped Softhale raise seed funding.
First patent was filed by the group –June 2013
Starting conceptual work on a new generation Soft Mist Inhaler (SMI) –August 2012
the founding members of Softhale met and started their conceptual work on a new generation Soft Mist Inhaler (SMI). The team had proven expertise in the microfluidic, medical device, pharmaceutical, and business development competencies, and the collaboration resulted in a business concept to start a pharmaceutical company.